GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Artrya Ltd (ASX:AYA) » Definitions » Research & Development

Artrya (ASX:AYA) Research & Development : A$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Artrya Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Artrya's Research & Development for the six months ended in Dec. 2023 was A$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

Artrya Research & Development Historical Data

The historical data trend for Artrya's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artrya Research & Development Chart

Artrya Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Research & Development
- - - -

Artrya Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Research & Development Get a 7-Day Free Trial - - - - -

Artrya Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artrya  (ASX:AYA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Artrya Research & Development Related Terms

Thank you for viewing the detailed overview of Artrya's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Artrya Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Artrya Ltd (ASX:AYA) » Definitions » Research & Development
Comparable Companies
ASX:PHX ASX:PCK ASX:SHG ASX:BB1 ASX:RHT ASX:HIQ ASX:IME ASX:EMD ASX:ALC ASX:VFX GEHC VEEV ASX:PME SOLV DOCS HQY WAY TSE:2413 TEM NSE:IKS
Traded in Other Exchanges
N/A
Address
1257 Hay Street, West Perth, WA, AUS, 6005
Website
https://www.artrya.com
Artrya Ltd is a medical technology company. It is engaged in the development and commercialization of Artrya Salix, its patented artificial intelligence platform that detects, diagnoses, and helps address coronary artery disease. The company is managed based on a single segment, being the development of AI-driven CCTA image analysis technology.

Artrya Headlines

No Headlines